Publication at First Faculty of Medicine, Faculty of Medicine in Hradec Králové |
2016
Abstract
We presented a retrospective evaluation of toxicity and efficacy in 14 patients with mCRPC treated by cabazitaxel. Cabazitaxel demonstrated favorable profile of toxicity and efficacy in treatment of metastatic castration-resistant prostate cancer in clinical practice.